tiprankstipranks
Sarepta Therapeutics (MX:SRPT)
:SRPT
Mexico Market
SRPT
Sarepta Therapeutics
RESEARCH TOOLSreports

Sarepta Therapeutics (SRPT) Stock News & Sentiment

1 Followers
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
Premium
Ratings
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
2d ago
SRPT
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
Premium
Ratings
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
2d ago
SRPT
Sarepta’s ENHANCE Study: Post-Marketing Safety Push for ELEVIDYS Could Shape SRPT’s Next Leg
Premium
Company Announcements
Sarepta’s ENHANCE Study: Post-Marketing Safety Push for ELEVIDYS Could Shape SRPT’s Next Leg
14d ago
SRPT
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
Premium
Company Announcements
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
1M ago
SRPT
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged
Premium
Ratings
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged
1M ago
SRPT
Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook
Premium
Ratings
Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook
1M ago
SRPT
Sarepta Therapeutics Inc. (SRPT) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Sarepta Therapeutics Inc. (SRPT) Q2 Earnings Cheat Sheet
1M ago
SRPT
More MX:SRPT News >

SRPT News on the Web

Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
TipRanks News
Bullish
FDA Win Sends Sarepta Soaring On Duchenne Gene Bet
TipRanks News
Bullish
Q2 2026 Sarepta Therapeutics Inc Earnings Call Transcript
GuruFocus News
Neutral
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)
TipRanks News
Bearish
Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13
TipRanks News
Bearish
Analysts Offer Insights on Healthcare Companies: Compugen (CGEN), Telix Pharmaceuticals (OtherTLPPF) and Sarepta Therapeutics (SRPT)
TipRanks News
Bearish
Citi sees intensifying competition for Sarepta from Dyne Therapeutics
TipRanks News
Neutral
Bank of America Securities Sticks to Its Sell Rating for Sarepta Therapeutics (SRPT)
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
MX:SRPT
Sector Average
Media Buzz
This Week8 articles
Weekly Average2 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MX:SRPT’s Media Buzz Sentiment?
8 articles about MX:SRPT were published this week. In an average week, 2 articles are published.
    What is MX:SRPT’s weekly average amount of articles?
    In an average week, 2 articles about MX:SRPT are published.
      What is MX:SRPT’s News Sentiment?
      50% of articles about MX:SRPT were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        HCMHUTCHMED
        GHGuardant Health
        BIIBBiogen
        MODDModular Medical
        SMMTSummit Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week